February 27, 2023: NCHR urges Congress to support the decision by the Centers for
Medicare and Medicaid Services (CMS) to limit the coverage of newly approved Alzheimer’s
drugs until the treatments have been shown to have a meaningful, clinical benefit that outweighs
the risks for the Medicare population.
On Health Policy
Testimony of Dr. Diana Zuckerman before the House of Delegates Environment & Transportation Committee For HB 299
February 15, 2023: NCHR testified before the Maryland House Environment Committee to support HB299, which would require transparency about the use and disposal of artificial turf and infill. That will enable communities to make informed decisions about the environmental and health impact of these materials.
Read More »Testimony of Dr. Diana Zuckerman at CMS MEDCAC Meeting On Coverage with Evidence Development
February 13, 2023: In testimony before CMS MEDCAC, NCHR strongly supported the new proposals to improve the quality of research needed to decide Medicare coverage evidence. We especially appreciate the focus on clinically meaningful benefits for patients that are representative of Medicare beneficiaries
Read More »NCHR Comments on USPTO-FDA Collaboration and Engagement
February 6, 2023: NCHR’s public comments strongly support FDA’s decision to prioritize USPTO-FDA collaboration. Access to generic drugs and biosimilars is critically important and abuse of the patent system remains a major barrier. We are hopeful that meaningful collaboration between the FDA and the USPTO will result in substantial improvements.
Read More »NCHR Comments on HHS Proposed Rule Regarding Confidentiality of Substance Use Disorder (SUD) Patient Records
January 31, 2023: NCHR’s public comment criticizes the HHS plan to align privacy standards with HIPAA instead of Part 2. We are concerned that loss of privacy for patients with substance abuse disorder (SUD) could stigmatize them or discourage them from seeking treatment.
Read More »